Sayed, S., Kumar, R., Zarba, M., Taleb, A., Mairs, S., Basappa, N. S., Kolinsky, M. P., Mahoney, M. E., Navani, V., Cheng, T., Lee-Ying, R. M., Karim, S., North, S. A., Heng, D. Y. C., Yip, S. M., Alimohamed, N. S. (2026). Dose modifications, toxicity, and survival with enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): Real-world experience in Alberta, Canada.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.188